Neurological Surgery 脳神経外科44巻8号

2016年08月発行

総説

2016WHO中枢神経系腫瘍分類—改訂の経緯と展望

著者： 小森隆司¹ 佐々木光² 𠮷田一成²

所属機関： ¹東京都立神経病院検査科 ²慶應義塾大学医学部脳神経外科

ページ範囲：P.625 - P.635

Ⅰ．はじめに
　世界保健機関（World Health Organization：WHO）の脳腫瘍分類（Classification of Tumours of the Central Nervous System）は1979年に初版が発行されて以来，診断技術の進歩に合わせて改訂を重ね，今回，第4版の改訂版（WHO2016）^9,10)が発行された（2016年5月）．この改訂版は分子分類を初めて取り入れるなど従来の基本的な考え方が大きく変更され，事実上の第5版と呼ぶべきものであった．しかしながら，WHO分類は全臓器が歩調を合わせて改訂を行う決まりとなっており，他臓器の第4版が終了していない現段階では第5版を謳うことができないという縛りがあったため，今回は「改訂版」にとどまった．
　本稿では新分類の理解の一助とするために，改訂に至った経緯や背景などを中心に解説を試みる．

参考文献

1) Buckner JC, Shaw EG, Pugh SL, Chakravarti A, Gilbert MR, Barger GR, Coons S, Ricci P, Bullard D, Brown PD, Stelzer K, Brachman D, Suh JH, Schultz CJ, Bahary JP, Fisher BJ, Kim H, Murtha AD, Bell EH, Won M, Mehta MP, Curran WJ Jr：Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. N Engl J Med 374：1344-1355, 2016

2) Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN：Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90：1473-1479, 1998

3) Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D, Buckner J, Fink K, Souhami L, Laperierre N, Mehta M, Curran W：Phase Ⅲ trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma：Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24：2707-2714, 2006

4) Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, Fink K, Souhami L, Laperriere N, Curran W, Mehta M：Phase Ⅲ trial of chemoradiotherapy for anaplastic oligodendroglioma：long-term results of RTOG 9402. J Clin Oncol 31：337-343, 2013

5) Cairncross JG, Wang M, Jenkins RB, Shaw EG, Giannini C, Brachman DG, Buckner JC, Fink KL, Souhami L, Laperriere NJ, Huse JT, Mehta MP, Curran WJ Jr：Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. J Clin Oncol 32：783-790, 2014

6) Hayashi S, Sasaki H, Kimura T, Abe T, Nakamura T, Kitamura Y, Miwa T, Kameyama K, Hirose Y, Yoshida K：Molecular-genetic and clinical characteristics of gliomas with astrocytic appearance and total 1p19q loss in a single institutional consecutive cohort. Oncotarget 6：15871-15881, 2015

7) 金村米博，市村幸一，正札智子，山崎麻美，渋井壮一郎，新井　一，西川　亮：髄芽腫の分子遺伝学的診断とその標準化．脳外誌24：436-444, 2015

8) Louis DN, Perry A, Burger P, Ellison DW, Reifenberger G, von Deimling A, Aldape K, Brat D, Collins VP, Eberhart C, Figarella-Branger D, Fuller GN, Giangaspero F, Giannini C, Hawkins C, Kleihues P, Korshunov A, Kros JM, Beatriz Lopes M, Ng HK, Ohgaki H, Paulus W, Pietsch T, Rosenblum M, Rushing E, Soylemezoglu F, Wiestler O, Wesseling P：International Society of Neuropathology--Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol 24：429-435, 2014

9) Louis DN, Perry A, Reifenberges G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW：The 2016 World Health Organization Classification of Tumors of the Central Nervous System：a summary. Acta Neuropathol 131：803-820, 2016

10) Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Ellison DW, Figarella-Branger D, Perry A, Reifenberger G, von Deimling A：WHO Classification of Tumours of the Central Nervous System. International Agency for Research on Cancer, Lyon, 2016

11) 中里洋一：改訂された脳腫瘍WHO分類．Brain Nerve 60：59-77, 2008

12) Perry A：A blustery wind of change. Brain Pathol 24(3)：i-ii, 2014. DOI：10.1111/bpa. 12143

13) Perry A：WHO's arrived in 2016! An updated weather forecast for integrated brain tumor diagnosis. Brain Tumor Pathol 33：157-160, 2016

14) Sasaki H, Hirose Y, Yazaki T, Kitamura Y, Katayama M, Kimura T, Fujiwara H, Toda M, Ohira T, Yoshida K：Upfront chemotherapy and subsequent resection for molecularly defined gliomas. J Neurooncol 124：127-135, 2015

15) 佐々木　光，𠮷田一成：神経膠腫の分子診断と個別化治療．No Shinkei Geka 44：185-201, 2016

16) 佐々木　光：神経膠腫の化学療法．脳外速報26：475-481, 2016

17) Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO；European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups；National Cancer Institute of Canada Clinical Trials Group：Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352：987-996, 2005

18) Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, Taylor LP, Lieberman F, Silvani A, Fink KL, Barnett GH, Zhu JJ, Henson JW, Engelhard HH, Chen TC, Tran DD, Sroubek J, Tran ND, Hottinger AF, Landolfi J, Desai R, Caroli M, Kew Y, Honnorat J, Idbaih A, Kirson ED, Weinberg U, Palti Y, Hegi ME, Ram Z：Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma：a randomized clinical trial. JAMA 314：2535-2543, 2015

19) Suzuki H, Aoki K, Chiba K, Sato Y, Shiozawa Y, Shiraishi Y, Shimamura T, Niida A, Motomura K, Ohka F, Yamamoto T, Tanahashi K, Ranjit M, Wakabayashi T, Yoshizato T, Kataoka K, Yoshida K, Nagata Y, Sato-Otsubo A, Tanaka H, Sanada M, Kondo Y, Nakamura H, Mizoguchi M, Abe T, Muragaki Y, Watanabe R, Ito I, Miyano S, Natsume A, Ogawa S：Mutational landscape and clonal architecture in grade Ⅱ and Ⅲ gliomas. Nat Genet 47：458-468, 2015

20) Taylor MD, Northcott PA, Korshunov A, Remke M, Cho YJ, Clifford SC, Eberhart CG, Parsons DW, Rutkowski S, Gajjar A, Ellison DW, Lichter P, Gilbertson RJ, Pomeroy SL, Kool M, Pfister SM：Molecular subgroups of medulloblastoma：the current consensus. Acta Neuropathol 123：465-472, 2012

21) van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ, Frenay M, Tijssen CC, Grisold W, Sipos L, Haaxma-Reiche H, Kros JM, van Kouwenhoven MC, Vecht CJ, Allgeier A, Lacombe D, Gorlia T：Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas：a randomized European Organisation for Research and Treatment of Cancer phase Ⅲ trial. J Clin Oncol 24：2715-2722, 2006

22) van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre JY, Bernsen HJ, Frenay M, Tijssen CC, Grisold W, Sipos L, Enting RH, French PJ, Dinjens WN, Vecht CJ, Allgeier A, Lacombe D, Gorlia T, Hoang-Xuan K：Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma：long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 31：344-350, 2013

23) Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, Sabel MC, Koeppen S, Ketter R, Meyermann R, Rapp M, Meisner C, Kortmann RD, Pietsch T, Wiestler OD, Ernemann U, Bamberg M, Reifenberger G, von Deimling A, Weller M：NOA-04 randomized phase Ⅲ trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 27：5874-5880, 2009